European Parliament
President.
Question No 25 by Ward Beysen 
Subject: Parallel trade
Is the Commission aware of the continual threats to legal parallel trade in medicines inside the EU, a process which saves Member State governments and European patients millions of euros each year?
Has it considered using Article 82 as a legal basis for ensuring pharmaceutical manufacturers play by the single market rules?

